Lode Gold Strengthens Board of Spin Co Gold Orogen Ahead of Tax-Efficient Spin-out
Toronto, Ontario--(Newsfile Corp. - March 7, 2025) - Lode Gold Resources Inc. (TSXV: LOD) (OTCQB: LODFF) ('Lode Gold' or the 'Company') is pleased to announce the proposed appointment of Bill Fisher and Rajesh Sharma to the Board of Directors of its upcoming spin-out company, Gold Orogen. The spin-out is scheduled for March 2025, with a shareholder meeting set for March 10, 2025, to approve the tax-efficient plan of arrangement.
The proposed appointments of Bill, Rajesh and the other Directors will be subject to shareholder approval at the Company's Annual General Meeting (AGM) on March 10, 2025. Their appointments will be finalized following the AGM.
The proposed Gold Orogen Board will include:
Hashim Ahmed
Wendy T. Chan
Chad Tappendorf
Ron Tomlinson
Jonathan Hill
Bill Fisher (newly proposed to be appointed)
Rajesh Sharma (newly proposed to be appointed)
Bill Fisher, BSc, P.Geo
Director (Proposed)
Bill has a successful track record, marked by notable exits. In the late 1990s, Bill served as Vice President of Exploration for Boliden AB, a major European mining and smelting company, where he managed 35 projects across nine countries. His career highlights include serving as Chairman of Aurelian Resources, which discovered the Fruta del Norte gold deposit in Ecuador, leading to the company's acquisition by Kinross Gold for $1.2 billion in 2008. Fisher also transformed GlobeStar Mining Corp. from an exploration company to an emerging mining company, developing the Cerro de Maimon copper/gold mine in the Dominican Republic, which was completed on time and under budget. This project was later sold to Perilya for $186 million.
With over 40 years in the mining industry, he is renowned for his expertise in exploration, development, and strategic leadership. His career began in Africa, where he spent a decade working on diamond exploration and mining projects, including significant discoveries of kimberlites in the Congo and contributions to exploration efforts in West Africa.
Currently, Bill serves as Chairman of GoldQuest Mining Corp., overseeing the development of a 3-million-ounce gold discovery in the Dominican Republic. He also holds directorships in several mining companies, including Inventus Mining and Churchill Resources, and previously served as Chairman of Treasury Metals, developing the Goliath Gold Project in Northwest Ontario.
Rajesh Sharma, ICD.D
Director (Proposed)
Rajesh brings extensive global leadership experience across the mining, exploration, metals, and international trade sectors. His career highlights include leading large-scale mining start-ups and exploration companies, as well as successfully completing several investment and acquisition deals. Within the Tata Group, Rajesh held multiple leadership roles, serving as CEO and Board member of various exploration, mining, and investment subsidiaries of Tata Steel in Canada and Africa. Additionally, he served as Executive in Residence at Investissement Québec. Rajesh holds degrees in management and engineering from IIT Roorkee and completed a scholarship program on Globalization and Leadership at the London School of Economics.
Biographies of the other existing Directors from Lode Gold joining the Board of Directors include:
Wendy T. Chan BSc, MBA, ICD.D
CEO
Wendy formerly held positions with Skeena, Roxgold and Novo Resources. She brings over 20 years of experience in developing and executing strategic plans for both Fortune 500 and entrepreneurial companies with global outreach.
Throughout her career, Wendy has demonstrated proficiency in managing businesses with full P&L responsibilities, consistently driving profitability. Her operational experience includes leading cross-functional teams and spearheading negotiations for multi-million-dollar projects. Wendy's global perspective is evident in her work on key development initiatives involving JVs, strategic alliances and mergers and acquisitions across diverse regions, including Asia, Australia, Africa and the Americas.
Hashim Ahmed, CPA
Interim Chairman Director
Hashim is a seasoned financial executive with over 20 years of experience in finance, accounting, tax and governance. He currently serves as Executive VP and CFO of Mandalay Resources.
Prior to joining Mandalay, Hashim held key positions in the mining industry, including Interim CEO of Nova Royalty and CFO of Jaguar Mining. His career also includes a significant tenure at Barrick Gold, where he spent seven years in progressively senior finance positions, both in Canada and with site finance teams in Chile. Hashim's expertise extends beyond the corporate realm, as he is a member of the Audit Committee of the Government of Ontario, showcasing his broad financial acumen and commitment to public service.
Chad Tappendorf, CFA, MBA
Director
Chad is a Partner at Coast Capital, a New York-based investment firm with focused interests in the mining sector. His extensive experience spans globally in both private and public equity investments, demonstrating a broad understanding of diverse industries and market dynamics.
Throughout his career, Chad has held board memberships across various sectors, including resources, logistics, real estate, and consumer goods. His expertise extends to managing multi-billion dollar private equity portfolios, showcasing his ability to handle large-scale investments and complex financial strategies. Chad's skill set encompasses the entire investment process, from identifying new opportunities and conducting thorough due diligence to performing valuations, negotiating deals, and structuring transactions and tax arrangements.
Jonathan Hill, Fellow AUSIMM, BSc (Hon) Econ Geo
Technical Director
Jonathan is a highly accomplished mining industry veteran with over 35 years of experience in exploration, project development, and mining operations worldwide. As the Founder and Principal Advisor of Exploration Outcomes Ltd., he leverages his extensive expertise to provide strategic guidance in the sector.
Throughout Jonathan's career, he has played a pivotal role in numerous world-class gold and copper discoveries across both greenfield and brownfield projects. His tenure at AngloGold Ashanti was particularly noteworthy, where he led multi-million-dollar greenfield exploration ventures in Brazil and Colombia. This experience has honed his skills in governance, exploration strategy, and management, making him a valuable asset in the mining industry.
Currently, Jonathan serves as a Director on the boards of several mining companies, including Spark Energy Minerals, Royal Road Minerals, Lavras Gold, and Avanti Gold. His previous role as VP of Exploration and later technical advisor for Jaguar Mining further underscores his comprehensive understanding of the industry.
Ron Tomlinson
Director
Ron is currently the CEO of Tomlinson Group. With over 35 years of experience in executive management, strategic acquisitions, real estate operations and investments, Ron has successfully expanded Tomlinson Group's operations across Canada and the United States. A seasoned manager and successful entrepreneur, he has driven the growth of the company into a vertically integrated organization with a strong focus on innovation and operational success.
Under Ron's leadership, Tomlinson Group has spearheaded numerous large-scale projects across diverse industries, including construction, environmental services, and infrastructure.
The Company is poised to leverage the diverse expertise of its well-rounded board to drive Gold Orogen's growth and achievements in the upcoming year.
Shares for Debt Issuance
Lode Gold is settling $231,180 of debts on the balance sheet by issuing 963,251 shares at $0.24 per unit to professional services contractors, management, and advisors. The share-for-debt transaction is subject to the approval of the TSX Venture Exchange in accordance with Policy 4.3, Shares for Debt, of the TSX-V corporate finance manual.
About Lode Gold
Lode Gold (TSXV: LOD) is an exploration and development company with projects in highly prospective and safe mining jurisdictions in Canada and the United States. In Canada, its Golden Culvert and WIN Projects in Yukon, covering 99.5 km 2 across a 27-km strike length, are situated in a district-scale, high grade gold mineralized trend within the southern portion of the Tombstone Gold Belt. A total of four RIRGS targets have been confirmed on the property. A NI 43-101 technical report has been completed in May 2024.
In New Brunswick, Lode Gold has created one of the largest land packages with its Acadian Gold JV Co; consisting of an area that spans 445 km 2 and a 44 km strike. McIntyre Brook covers 111 km 2 and a 17-km strike in the emerging Appalachian/Iapetus Gold Belt; it is hosted by orogenic rocks of similar age and structure as New Found Gold's Queensway Project. Riley Brook is a 335 km 2 package covering a 26 km strike of Wapske formation with its numerous felsic units. A NI 43-101 technical report has been completed in August 2024.
In the United States, the Company is advancing its Fremont Gold project. This is a brownfield project with over 43,000 m drilled and 23 km of underground workings. It was previously mined at 10.7 g/t Au in the 1930's. Mining was halted in 1942 due the gold mining prohibition in World War Two (WWII) just as it was ramping up production. Unlike typical brownfield projects that are mined out; only 8% of the veins have been exploited. The Company is the first owner to investigate an underground high grade mine potential at Fremont. The project is located on 3,351 acres of private and patented land in Mariposa County. The asset is a 4 km strike on the prolific 190 km Mother Lode Gold Belt, California that produced over 50,000,000 oz of gold and is instrumental in creating the towns, businesses and infrastructure in the 1800s gold rush. It is 1.5 hours from Fresno, California. The property has year-round road access and is close to airports and rail. An NI 43-101 MRE has been reported on March 5, 2025. A complete technical report will be filed 45 days later on SEDAR+.
Previously, in March 2023, the company completed an NI 43 101 Preliminary Economic Assessment ('PEA') for the Fremont Gold project. A sensitivity to the March 31, 2023 PEA at USD $2,000/oz gold gives an after-tax NPV of USD $370M and a 31% IRR over an 11-year LOM. At $1,750 /oz gold, NPV (5%) is $217M. The project hosts an NI 43-101 resource of 1.16 Moz at 1.90 g/t Au within 19.0 MT Indicated and 2.02 Moz at 2.22 g/t Au within 28.3 MT Inferred. The MRE evaluates only 1.4 km of the 4 km strike of Fremont property. Three step-out holes at depth (up to 1200 m) hit structure and were mineralized. All NI 43-101 technical reports are available on the Company's profile on SEDAR+ ( www.sedarplus.ca) and the Company's website ( www.lode-gold.com)
ON BEHALF OF THE COMPANY
Wendy T. Chan, CEO & Director
Information Contact
Winfield Ding
CFO
+1-(604)-977-GOLD (4653)
Kevin Shum
Investor Relations
+1 (604) -977-GOLD (4653)
Cautionary Note Related to this News Release and Figures
This news release contains information about adjacent properties on which the Company has no right to explore or mine. Readers are cautioned that mineral deposits on adjacent properties are not indicative of mineral deposits on the Company's properties.
Cautionary Statement Regarding Forward-Looking Information
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release includes 'forward-looking statements' and 'forward-looking information' within the meaning of Canadian securities legislation. All statements included in this news release, other than statements of historical fact, are forward-looking statements including, without limitation, statements with respect to the completion of the transaction and the timing thereof, the expected benefits of the transaction to shareholders of the Company, the structure, terms and conditions of the transaction and the execution of a definitive agreement, the timing of submission to the CSE and TSXV, Gold Orogen raising an additional $1,500,000 and the anticipated use of proceeds. Forward-looking statements include predictions, projections and forecasts and are often, but not always, identified by the use of words such as 'anticipate', 'believe', 'plan', 'estimate', 'expect', 'potential', 'target', 'budget' and 'intend' and statements that an event or result 'may', 'will', 'should', 'could' or 'might' occur or be achieved and other similar expressions and includes the negatives thereof.
Forward-looking statements are based on a number of assumptions and estimates that, while considered reasonable by management based on the business and markets in which the Company operates, are inherently subject to significant operational, economic, and competitive uncertainties, risks and contingencies. These include assumptions regarding, among other things: that the Company and GRM will be able to negotiate the definitive agreement on the terms and within the time frame expected, that the Company and GRM will be able to make submissions to the CSE and TSXV within the time frame expected, that the Company and GRM will be able to obtain shareholder approval for the transaction, that the Company and GRM will be able to obtain necessary third party and regulatory approvals required for the transaction, if completed, that the transaction will provide the expected benefits to the Company and its shareholders.
There can be no assurance that forward-looking statements will prove to be accurate and actual results, and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include adverse market conditions, general economic, market or business risks, unanticipated costs, the failure of the Company and GRM to negotiate the definitive agreement on the terms and conditions and within the timeframe expected, the failure of the Company and GRM to make submissions to the CSE and TSXV within the timeframe expected, the failure of the Company and GRM to obtain shareholder approval for the transaction, the failure of the Company and GRM to obtain all necessary approvals for the transaction, and r other risks detailed from time to time in the filings made by the Company with securities regulators, including those described under the heading 'Risks and Uncertainties' in the Company's most recently filed MD&A. The Company does not undertake to update or revise any forward-looking statements, except in accordance with applicable law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Politico
2 hours ago
- Politico
BIO chair: U.S. has a ‘crisis' on drug costs
Driving The Day NEW BIO CHAIR'S POLICY TAKE — The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump's second term. One of its chief lobbying arms is gearing up to take them on. Ahead of the Biotechnology Innovation Organization's annual convention this week in Boston, Genentech's Fritz Bittenbender — who was elected Monday as the group's board chair — chatted with Lauren about BIO's priority issues, distrust in science and medical institutions and its approach to geopolitical engagement. Pros can read the full Q&A, but here are some highlights and outtakes: An 'existential policy crisis': Bittenbender used the term to refer to debates around 'intellectual property, how do you pay for medicines, what kind of investments are we going to make at early-stage research' — all of which bring to mind Trump administration priorities like the most-favored-nation approach to bringing down drug prices and limiting National Institutes of Health spending on indirect costs in university research. 'We have a lot of sound-bite policy happening right now, and [most-favored-nation is] a great example of that,' he said, adding that the U.S. health system works much differently from those in allied European countries, often held up as examples of cheaper markets. How industry can combat distrust in science: Biotechs need to do a better job of communicating the benefits they bring to patients, and they need policymakers' help, Bittenbender said. 'Working with policymakers, and … bringing as much transparency to our industry as we possibly can — using real-world data and digital analytics more effectively to understand postmarketing studies of products on the market and being transparent about that,' he said. Federal job cuts: Regulatory uncertainty is an 'existential threat' to the industry amid the massive downsizing and restructuring of the Department of Health and Human Services, Bittenbender said. 'If it's going to take 10 or 15 years to bring a product to the market and $1 [billion] to $2 billion to do that, that's a significant investment over a long-term period. And for investors to want to do that, they have to know that there's a certain regulatory environment,' he said. 'They have to know that regulatory timelines are going to be met or exceeded.' The tariff threat: 'Our industry is a national security imperative for the country, and that means having essential medicines that patients really need manufactured here,' Bittenbender said. 'Hopefully, we won't see tariffs on the pharmaceutical industry, and we work in other ways to get manufacturing into the United States and to ensure that essential medicines that we need in times of emergency or pandemic are sourced from a place that we trust and that we know we can get them,' he added. IT'S TUESDAY. WELCOME BACK TO PRESCRIPTION PULSE. NPR reports on how music therapy can help cancer patients manage their stress and symptoms. Send your tips to David Lim (dlim@ @davidalim or davidalim.49 on Signal) and Lauren Gardner (lgardner@ @Gardner_LM or gardnerlm.01 on Signal). Eye on the FDA SECOND DMD DRUG DEATH — A second patient with Duchenne muscular dystrophy has died after taking Sarepta Therapeutics' Elevidys gene therapy, the company said, prompting a reevaluation of the drug's treatment protocol. The death occurred in a 15-year-old nonambulatory individual enrolled in the company's randomized, placebo-controlled trial intended to confirm the drug's benefit in patients who can't walk under the FDA's accelerated approval pathway. A company official said the latest death shares 'some similarities to the previous' death of a teenage boy earlier this year; both fatalities were due to acute liver failure, a known side effect of the viral vector gene therapy used in Elevidys. Sarepta said the signal has emerged only in patients who can't walk, which they consider a surrogate for disease progression. Sarepta President and CEO Douglas Ingram said the company wants to meet with the FDA 'as rapidly as possible' to establish a new immunosuppressive regimen for nonambulatory patients. Until that's implemented, the company has paused drug shipments for that population, as well as dosing for its clinical trial, it said. Response: HHS spokesperson Emily Hilliard said the FDA is treating the death 'with the highest level of concern' and 'will take all appropriate regulatory actions to protect patients during our review of gene therapy products.' The FDA is reviewing a cell therapy candidate from Capricor Therapeutics to treat DMD. The target date for a decision is Aug. 31. PDUFA PROBLEMS? KalVista Pharmaceuticals raised some eyebrows late last week after announcing that the FDA had disclosed it would miss its Tuesday PDUFA target for the drug sebetralstat, which is used as therapy for hereditary angioedema, 'due to heavy workload and limited resources.' The rare disorder causes episodes of swelling in various parts of the body and can sometimes be fatal. FDA Commissioner Marty Makary has repeatedly said medical product reviews would continue apace despite thousands of job cuts at the agency, and reviewers were not among the terminated workers. But employees charged with supporting review staff by booking travel and securing supplies were impacted, and drug companies remain concerned about attrition in the remaining workforce. HHS did not comment. In Congress EXPANDED ORPHAN EXEMPTION OUT — The Senate Finance Committee's reconciliation bill strips an effort by the House to expand a Medicare drug price negotiations exemption for orphan drugs to include medicines that treat multiple rare diseases or conditions. The Congressional Budget Office estimated the policy in the House bill would cost the federal government nearly $5 billion over 10 years, a figure groups like AARP and Patients For Affordable Drugs Now used to urge senators to keep the measure out of the Senate bill. But pharmaceutical companies argue the provision would incentivize additional investment in rare-disease drug development as the IRA exemption currently applies to orphan drugs that treat a single rare disease. SANDERS WANTS ACIP INVESTIGATION — Senate HELP ranking member Bernie Sanders (I-Vt.) wants his counterpart to open a bipartisan investigation into the removal of 17 members of the CDC's outside vaccine committee. In his letter to Sen. Bill Cassidy (R-La.), chair of the Health, Education, Labor and Pensions Committee, Sanders asked for 'serious oversight' of HHS Secretary Robert F. Kennedy Jr.'s actions regarding the Advisory Committee for Immunization Practices. 'Secretary Kennedy's reckless decision to fire these non-partisan scientific experts and replace them with ideologues with limited expertise and a history of undermining vaccines will not only endanger the lives of Americans of all ages, it directly contradicts a commitment he made to you before he was confirmed that he would not make any significant changes to this important Committee,' Sanders wrote to Cassidy. A spokesperson for Cassidy did not immediately respond to a request for comment. In the courts PURDUE SETTLEMENT 2.0 — All 50 states and several U.S. territories have agreed to sign onto a $7.4 billion settlement with Purdue Pharma and its principal owners, the Sackler family, that will resolve state and local government claims. 'The local government sign-on and voting solicitation process for this settlement moving forward will be contingent on bankruptcy court approval,' California Attorney General Rob Bonta's office said in a news release. 'A hearing is scheduled on that matter in the coming days.' The settlement ends the Sackler family's control of Purdue and prevents them from selling opioids in the country. Document Drawer The FDA's Psychopharmacologic Drugs Advisory Committee will meet on July 18 to discuss Otsuka Pharmaceutical's supplemental new drug application to approve Rexulti to treat adults with post-traumatic stress disorder in combination with sertraline. The FDA published final guidance outlining recommendations for generic drugmakers on how to submit a pre-submission facility correspondence that can be used to help the agency begin site assessments in advance of submitting an abbreviated new drug application. WHAT WE'RE READING The 17 dismissed members of the CDC's vaccine advisory panel published an op-ed in JAMA, saying their abrupt dismissal last week 'undermines the committee's capacity to operate effectively and efficiently, aside from raising questions about competence.' HHS awarded an Arizona law firm $150,000 for its expertise on the Vaccine Injury Compensation Program, NOTUS' Margaret Manto reports, suggesting it's considering policy changes to the 40-year-old system.
Yahoo
2 hours ago
- Yahoo
The AI Paradox: Artificial Intelligence Supporting Business Growth While Fueling Fraud
New BILL survey of 1,000 business leaders shows AI is simultaneously fighting and fueling financial crime SAN JOSE, Calif., June 17, 2025--(BUSINESS WIRE)--AI and automation are reshaping business priorities, according to a new report from BILL (NYSE: BILL), a leading financial operations platform for small and midsize businesses. The 2025 BILL Report: Building the Future of Finance, which surveyed business owners and finance leaders, reveals that businesses across the country are increasingly turning to AI to help them improve cash flow, fight fraud, and adapt to economic uncertainty. "AI is a factor influencing every finance leader as they are making operational decisions to run their business – from fighting fraud, to growing cash flow, automating manual tasks or adapting their operations," said René Lacerte, CEO and Founder of BILL. "Leaders are clear-eyed about the need and opportunity to transform their operations, and as companies change how they work, who they work with, and how they win, there is one certainty: the finance leader's job of tomorrow will look very different to anything we've seen before." Key findings of the survey include: Fraud is on the rise, and AI is both an asset and a liability. An overwhelming 92% of businesses are worried about fraud, with 56% reporting an increase in fraud attempts in the last year. AI is both an ally and an adversary in this fight: 54% report AI is improving their ability to detect fraud, but 46% say AI is increasing their overall fraud risk. The result is an innovation battle that makes fraud an increasingly complex problem – with AI right at the center. Established businesses are leading the way on AI adoption. Businesses started in the last 12 months reported the highest levels of skepticism around AI, while established businesses were the most enthusiastic. Among businesses operating for over 20 years, 70% believe AI will strengthen financial forecasting, compared with just 47% of businesses under 5 years old. AI is breaking down barriers for start-ups: 68% believe AI will make it easier to start a new business, and nearly two-thirds believe it will help survive the first year (63%) and reach the five-year milestone (61%). Businesses lean into smart cash flow management. Companies are recalibrating their strategies for success amidst economic uncertainty. In the next six months, businesses are planning to diversify suppliers (40%), increase prices (39%), and accelerate automation (38%) to stay competitive. The filing cabinet is in the crosshairs: Businesses have bold timelines for achieving paperless operations. One-third plan to be paperless by 2026, while 90% believe going paperless within five years is realistic. Cash flow blind spots create risk: Most businesses lack real-time financial visibility. Almost two-thirds of businesses can't access their current cash positions on demand. For one in five businesses, it can take days or weeks. Half of businesses see better cash flow management as essential to enable faster responses to opportunities. Accounting talent shortage forces businesses to innovate: Due to an ongoing talent shortage in the accounting industry, 77% of businesses anticipate rising costs of accounting services, while 60% are preparing for the possibility of handling more accounting work in-house. At the same time, 56% maintain strong relationships with their accounting partners. To read the full report, visit About the Study The 2025 BILL Report: Building the Future of Finance, conducted by Rep Data, was fielded in March 2025. Respondents included 1,003 business owners and financial decision-makers in the U.S. with 1-1,000 employees. The survey sample was not drawn from a list of BILL customers. About BILL BILL (NYSE: BILL) is a leading financial operations platform for small and midsize businesses (SMBs). As a champion of SMBs, we are automating the future of finance so businesses can thrive. Our integrated platform helps businesses to more efficiently control their payables, receivables and spend and expense management. Hundreds of thousands of businesses rely on BILL's proprietary member network of millions to pay or get paid faster. Headquartered in San Jose, California, BILL is a trusted partner of leading U.S. financial institutions, accounting firms, and accounting software providers. For more information, visit View source version on Contacts Press Contact: Lauren Johnspr@ IR Contact: Karen Sansotksansot@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
EU-China talks on minimum pricing for Chinese EVs welcomed by Smart CEO Dirk Adelmann
TURIN — The head of German-Chinese electric brand Smart gave a cautious welcome to a potential plan to impose minimum prices on Chinese EVs exported to Europe. The price management system would replace the European Union's tariffs on Chinese battery-electric cars and could help allay fears about subsidized EVs from China flooding European markets. China's commerce ministry said June 7 that talks with the EU on setting minimum prices for Chinese-made electric vehicles have 'entered final stages.' Sign up for the Automotive News Europe Interview of the Month newsletter delivering exclusive interviews with top auto executives. RELATED ARTICLE: Smart #5 midsize electric SUV is a big step up in size, and price, for Mercedes/Geely brand 'Whatever they come to as an agreement will be better than the tariffs we have at the moment,' Dirk Adelmann, CEO of Smart Europe, told the 2025 Automotive News Europe Congress here June 12. 'For us, it will still be a hit, but it will be much more digestible than current tariffs.' Smart is a joint venture between Geely and Mercedes-Benz that builds its electric cars in China. The brand has been hit hard by the EU tariffs that add 18.8 percent duty to the 10 percent already charged on the cars it exports to Europe. Adelmann said the company had to pass some of the cost increase on to customers in the form of a price hike from January. Smart's European sales fell 38 percent to 3,611 in the first four months, according to figures from market analyst Dataforce. Adelmann said he was 'cautiously optimistic' that there will be a negotiated solution to the tariff situation by the end of this year. Minimum prices would be most welcomed by automakers whose cars have a lower landing price. 'It very much depends on your current import value that you have. Some competitors have a rather low import value so there's a much higher benefit to go to minimum pricing versus tariffs,' Adelmann said. The minimum price plan has seen pushback from some Chinese car companies. Philippe Houchois, from Jefferies investment bank, told the Congress: 'It seems like a gift to the Chinese to sell cars at a better price margin, but we hear the Chinese don't want it because they want to be able to sell cheaper cars.' Reform of the tariff system is needed, he added. 'I think it was an ill-defined policy. It took a lot of time, a lot of effort to try to construct something that is not working.' Stellantis-backed Leapmotor, which sells the low-cost TO3 small electric car in Europe, opposes the minimum price strategy, the Financial Times reported. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
